The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of Senior Leadership, Programs, and Shared Core Facilities. A core grant to support the UMCCC was initially awarded by the NCI in 1988, with continuous funding since then. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of defined clinical, basic, and prevention programs in cancer research and the development of shared core resources. In 1997 the Center moved into a new $88 million facility which houses the Center's outpatient clinics as well as many of its research laboratories. The Cancer Center has continued to experience considerable growth over this grant period with 70 new faculty recruited and an 85% increase in NCI funding. The Cancer Center's 13 research programs include the basic research programs in Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences, and Molecular Imaging. Clinical research programs include Prostate/Urological, Breast, Leukemia/Lymphoma-BMT, Gl, Childhood Cancers, and Head & Neck cancers. The prevention programs include two programs: Biomedical Prevention and Socio-Behavioral. Support is requested for a total of 16 shared core facilities. These include Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA Sequencing, Morphology, Flow Cytometry, Experimental Irradiation, Animal Facility, Transgenic Mouse, Vector Core, Immune Monitoring, cDNA Affymetrix and Microarray and three new cores including Proteomics, Bioinformatics, and Health Communications. Funds are also requested for development, planning and evaluation, and administration to support Center goals. The Medical Center has made substantial commitments to the Cancer Center of approximately $175 million. Its 285 UMCCC members receive over $82 million in research funding, including over $37 million in annual direct NCI support. The UMCCC has had a major impact on cancer research as evidenced by publishing at least 315 articles in high impact journals, placing 52% of UMCCC intervention accruals onto investigator-initiated trials and consistently ranking among the top ten Cancer Centers nationally for NCI funding over this grant period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications